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Abstract
Background & aims
In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti-
(IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3. In this paper,
however, it is intended to extend the mentioned model by assessing the expression mRNA
levels of IL-27 and TGF-β1 as well as the changes of plasma levels of IL-27, TGF-β1, IL-
17A, IL-10, and IL-6 after treatment by vitamin D3.
Method
Venous blood samples were drawn from Healthy Participants (HP, n = 25) and First-Degree
Relative Participants (FDRP, n = 25) as control groups and Multiple Sclerosis Participants
(MSP, n = 25) before and after eight weeks of supplementation with 50000 IU vitamin D3.
The mRNA expression and plasma concentrations were gauged by using Real-Time PCR
and ELISA assay, respectively.
Results
The mRNA surfaces of IL-27, as well as TGF-β1, were up-regulated. However, the plasma
levels of TGF-β1, IL-17A, and IL-6 were significantly different among the three groups. In
addition, the plasma levels of IL-27, TGF-β1, IL-10, IL-17A, and IL-6 significantly changed
following the administration of vitamin D3.
Conclusion
The findings of this paper illustrate that anti-inflammatory cytokines could have a key role in
immunomodulatory functions due to their anti-inflammatory functions. To conclude, this
might contribute to preventing the pathophysiological process of MS. Also, the proposed
PLOS ONE
PLOS ONE | https://doi.org/10.1371/journal.pone.0231145 April 6, 2020 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Hashemi R, Hosseini-Asl SS, Arefhosseini
SR, Morshedi M (2020) The impact of vitamin D3
intake on inflammatory markers in multiple
sclerosis patients and their first-degree relatives.
PLoS ONE 15(4): e0231145. https://doi.org/
10.1371/journal.pone.0231145
Editor: Stella E. Tsirka, Stony Brook University,
UNITED STATES
Received: October 13, 2019
Accepted: March 17, 2020
Published: April 6, 2020
Copyright: © 2020 Hashemi et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: Dr. Seyed Rafie Arefhosseini has received
financially supported by Nutrition Research Center,
Tabriz University of Medical Sciences, Tabriz, Iran
(https://nut-rc-en.tbzmed.ac.ir/). The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
model could be used as a preventive way on disposed people to multiple sclerosis, particu-
larly in first degree relatives of these patients.
1. Introduction
Multiple Sclerosis (MS) is known to be an autoimmune and inflammatory disorder of the Cen-
tral Nervous System (CNS) which, is recognized by chronic inflammation, demyelination of
axons, neuronal injuries, and disabilities affecting approximately 2.5 million people world-
wide, the majority of which being women [1]. It is proposed that the combination of genetic
and environmental factors are the most significant MS risk factors. Furthermore, a lack of vita-
min D3 is a determinant risk factor, as well as frequently reported environmental factors in the
etiology of MS regardless of the geographical latitude and viral infections [2, 3]. The underly-
ing mechanisms of pathology and etiology of MS have not been dissolved yet, but evidence has
presumed that immunomodulatory and anti-inflammatory treatments can delay MS develop-
ment. According to the prior note, it has been suggested that vitamin D3 can have a major role
in immune regulation in MS [2, 4].
It has been suggested that perhaps this disorder depends on the dysregulation of pro- and
anti-inflammatory cytokines. Pro-inflammatory cytokines can boost the permeability of the
Blood-Brain Barrier (BBB), allowing for the neurodegeneration and demyelination of the CNS;
while anti-inflammatory cytokines can repress the secretion of pro-inflammatory cytokines [5].
For this reason, it appears that inflammation can play a considerable role in the degeneration of
brain axons and neurons in MS patients. Furthermore, evidence has indicated that the ratio
between pro- and anti-inflammatory is high in MS patients with a vitamin D3 deficiency. Vita-
min D3 has a probable immune-modulatory effect which, changes the equilibrium between
anti- and pro-inflammatory interleukins in favor of anti-inflammatory cytokines. So, the lack of
vitamin D3 is possible to cause inflammatory situations in MS patients [2, 4, 6].
Interestingly, Interleukin-27 (IL-27) possesses a dual function or pleiotropic, as anti- or
pro-inflammatory properties, in a variety of autoimmune diseases such as MS. Primarily, IL-
27 was proposed to provoke pro-inflammatory state by meliorating T-helper 1 (Th1) differen-
tiation from naïve T cells in early immune response via Signal Transducer and Activator of
Transcription 1 (STAT1) [7–9]; however, subsequent work using human and animal models
of MS have indicated that IL-27 has considerable inhibitory influences on Th1, Th2, and Th17
(IL-17A and IL-17F) subsets of T cells, and on Antigen-Presenting Cells (APCs) function. On
the same note, a few studies have indicated the protective role of IL-27 in Th1/Th17-mediated
immune diseases [10]. Nevertheless, recent studies have emphasized the anti-inflammatory
aspect of IL-27 and achieved further data by promoting inducible regulatory T (T-reg) cells to
secrete IL-10. Also, IL-27 powerfully provoked the differentiation of Cluster of Differentiation
4+ (CD4+) and CD8+ effector T cells to IL-10, T-bet, and Interferon-γ (IFN-γ) [7, 8, 11, 12].
Moreover, Transforming Growth Factor-β (TGF-β) has been recognized as a pleiotropic cyto-
kine with remarkable immunomodulatory impacts which, is mainly produced by T-reg cells to
manage autoimmune diseases. However, this paradoxical role of TGF-β relies on the cell sur-
face co-receptors, the differentiation state of T cells, and incitement situation [13, 14]. Equally
important, IL-27 works together with TGF-b to further enhance Type 1 regulatory (Tr1)-like
cells that produce large amounts of IL-10 and IFN-γ and decrease IL-17A and IL-17F produc-
tion [15]. Nevertheless, it is notable that TGF- β1 promotes differentiation of naïve CD4+ T
cells into Foxp3+ Tregs through signal STAT5, thereby increasing the expression of anti-
inflammatory cytokines like IL-10. Additionally, TGF- β1 plays a preventative role in terms of
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the entrance of sensitized T cells into the CNS and consequently quells the production of pro-
inflammatory cytokines [14, 16, 17]. Naïve CD4+ T cells can nonetheless be converted into
immature Th17 in the presence of IL-6 and via signal STAT3. Subsequently, pathogenic matu-
ration of Th17 cells, such as IL-17A, IL-17F, and IL-22 are released in the presence of IL-23
[17]. Up to now, the limited studies have researched the relation between vitamin D3 and
expression of IL-27 and TGF- β1 in MS patients. Vitamin D3 could both directly and indi-
rectly, upregulate the expression of IL-27 and TGF- β1. All the same, they are not enough and
need to clarify more the precise role of vitamin D3 in regulating them [13, 18, 19].
Due to the highlighting role of genetics in MS which has somewhat remained obscure, in
our previous [5] and present studies, attempts were conducted to introduce nutrition geno-
mics or nutrigenomics as a new potential therapeutic method in afflicted patients and prohib-
iting the illness in other people, especially in the first-degree relatives of MS patients.
According to IL-27 and TGF- β1 being key regulators of IL-10, IL-17A, and IL-6, this paper
highlights that the up-regulation of IL-27 and TGF- β1 by vitamin D3 increases the expression
of IL-10, as well as down-regulates IL-17A and IL-6.
2. Experimental procedures
2.1. Ethical codes and patient consent
The study protocol was reviewed and approved by the Iranian Registry of Clinical Trials
(IRCT20100407003655N4) and Ethics Committee of Tabriz University of Medical Sciences,
Iran (code of ethics: IR.TBZMED.REC.1397.608) before the recruitment of participants. Writ-
ten informed consent was also received from all patients and control groups; besides, they
were given a choice to withdraw from the study upon their willingness.
2.2. Study groups and intervention
Sample selection and supplementation design were discussed in our previous publication [5]. In
short, the subjects registered into the present study were divided into three groups: 1) MS partici-
pants (MSP, n = 25) as the first treatment (case) group along with two control groups including 2)
First degree relatives of MS participants as the second group (FDRP, n = 25) such as their daugh-
ter, son, brother, or sister and 3) Healthy participants (HP, n = 25) as the third group. The study
was conducted on the 19th of February, 2017, and ended on the 10th of June, 2017. To be
included in this study, participants were 1) between 20 to 40 years of age, 2) willing to take part in
the study, 3) able to donate blood samples, and 4) of no family kinship with MS patients for HPs.
Additionally, the exclusion criteria were: 1) taking medicines that interact with vitamin D3, 2)
Malabsorption, 3) gestation and lactation, and 4) vitamin D3 and calcium supplementation in the
last one month. After applying the inclusion and exclusion criteria, a total number of 25 partici-
pants were then randomized into each group by using a simple random sampling method.
The demographic and disease characteristics of the study have recapped in Table 1. The
first and second groups were also picked out from Ardabil MS Society and, the patients were
confirmed based on McDonald’s criteria and by a certified neurologist [17]. What is more, the
HP was selected from the Ardabil University of Medical Sciences. All groups pulled down
50,000 IU of vitamin D3 orally every Friday with their lunch breaks for two months. As previ-
ously described, before and after the administration of vitamin D3, five milliliters whole blood
samples were drawn from the selected participants, and the serum levels of 25-(OH) vitamin
D3 were measured immediately after serum separation by using electrochemiluminescence
(ECL) assay [5]. A certified laboratory performed all measurements in the Genetics Laboratory
at the Imam Khomeini Hospital and Biochemistry laboratory in the Research Center, Ardabil
University of Medical Sciences.
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2.3. RNA isolation and real-time PCR analysis for IL-27 and TGF-β1
The MN kit (MACHEREY-NAGEL, Germany) was applied to extract total RNA of Peripheral
Blood Mononuclear Cells (PBMCs), which were collected in anti-coagulant EDTA tubes, based
on the manufacturer’s orientations. Purity, concentration, and integrity of total RNA were con-
firmed by nano-drops (Thermo Scientific), gel electrophoresis, and spectrometry. Afterward,
the synthesis of cDNA was made with five μg of the total RNA by using a Random Hexamer
Primer through HyperScript™ Reverse Transcriptase (GeneAll, South Korea) in 20 μl total reac-
tion mixture. The mRNA expression levels of IL-27 and TGF-β1 genes were assessed with
appropriate primers and probes and were normalized with the housekeeping gene β-actin. Suit-
able primers and probes sequences for IL-27p28 (Forward: GGAGCGTCTCTGCTTCATCT;
Reverse: AGCTGCATCCTCTCCATGTT; Probes: FAM-CGCTTCAGCCCTTCCATGCC) [20],
TGF-β1: (Forward: CAGCAACAATTCCTGGCGATA; Reverse: AAGGCGAAAGCCCTCAATTT;
Probe: FAM- CTGCTGGCACCCAGCGACTCG, and β-actin (Forward: TCACCCACACTGTGCC
CATCTACGA; Reverse: CAGCGGAACCGCTCATTGCCAATGG; Probe: FAM-ATGCCCTCCCC
CATGCCATC) [21]—as a housekeeping control- were selected. Quantitative Real-time PCR was
fulfilled for mRNA expression on a Roche Light cycler 96 (version: 1.1.0.1320, Germany) using
12.5 μl of RealQ Plus 2x Master Mix for probe (Amplicon, Denmark), 250 nM of the TaqMan
probe, 500 nM of each forward and reverse primers, and 4 μl of synthesized cDNA solution in
total volume of 25 μl. Finally, the amplification of PCR was concluded through the following
schedule: an initial warming step for ten minutes at 94˚C, followed by a denaturation step at
94˚C for fifteen seconds, and finally, an annealing/extension one for sixty seconds at 60˚C.
2.4. Measurement plasma levels of IL-17A, IL-6, IL-10, IL-27, and TGF- β1
by ELISA
Here, five milliliters of the entire blood samples were taken at the beginning and the end of
the intervention period and were collected in anticoagulant tubes containing ethylenediami-
netetraacetic acid (EDTA), the blood samples were centrifuged at room temperature for ten
minutes at 3000 rpm to separate the plasma, following which the plasma samples were
Table 1. Demographic and disease characteristics.
Variables MSP (n = 25) FDRP (n = 25) HP (n = 25)
MS family�
Brother 1(4%) 5(20%) -
Sister 3(12%) 12(48%) -
Daughter 1(4%) 5(20%) -
Son - 3(12%) -
MS History�
Yes 5(20%) 25(100%) -
No 20(80%) - 25(100%)
Duration of disease(year)�� 8.1±5.8 - -
Sex�
Female 21(84%) 17(68%) 20(80%)
Male 4(16%) 8(32%) 5(20%)
Age(year)�� 32.6±6 27.4±6 31.7±4.3
The data are presented as frequency (percent) for categorical � variables and as mean ± SD for numeric normal ��
variables. Abbreviation: MSP, Multiple Sclerosis Participants; FDRP, First-Degree Relative Participants; HP, Healthy
Participants.
https://doi.org/10.1371/journal.pone.0231145.t001
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immediately frozen at– 80˚C until analyzed. According to the manufacturer’s instructions, the
plasma concentration of IL-17A, IL-6, IL-10, IL-27, and TGF- β1 from MSP, FDRP, and HP
were determined by using Enzyme-linked Immunosorbent Assay (ELISA) kits (Diaclone, SAS,
France). The kits’ sensitivities for these cytokines were 2.3 pg/ml, 2 pg/ml, 5 pg/ml, 12.8 pg/ml,
and 9 pg/ml, respectively.
2.5. Statistical analysis
The statistical analysis was fulfilled through SPSS Statistics Version 23.0 Software (SPSS Inc.,
Chicago, IL, USA) and GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA).
Comparisons among groups were assessed by using a One-way analysis of variance (ANOVA),
followed by post-hoc Tukey’s test. After that, within-group comparisons were surveyed by the
Paired t-test. The data were then expressed in a mean±standard deviation (SD) format for the
normal numeric variables. Notably, the fold change expression of each gene was calculated by
a ratio = 2−ΔΔCT formula, and the amplification efficiency between the target mRNA expres-
sion and β-actin was measured by the ΔΔCT method [22]. Finally, P-values of less than 0.05
was considered significant in all of the analyses.
3. Results
3.1. Clinical features
The flow diagram has been illustrated in Fig 1 as well as vitamin D3 serum levels and the
expression mRNA levels of IL-17A, IL-6, and IL-10 in S1 Table [5].
3.2. The mRNA expressions of IL-27 and TGF- β1 before and after
intervention
Before the intervention, the test of one-way ANOVA elucidated differences in the PBMCs lev-
els of IL-27 (P<0.001) and TGF-β1 (P<0.001) among the study groups. Since there is an
Fig 1. Enrollment and selection of participants allocated to groups by simple random sampling.
https://doi.org/10.1371/journal.pone.0231145.g001
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inverse relationship between ΔCT and mRNA expression, the results of this study clarified the
mRNA expression of either IL-27 or TGF-β1 are high in MSP, FDRP, and HP, respectively
[ΔCT IL-27: MSP: 5.93±1.49 vs. FDRP: 7.54±1.28 vs. HP: 8.09±1.23; ΔCT TGF-β1: MSP: 6.49
±1.13 vs. FDRP: 7.18±1.66 vs. HP: 8.06±1.16]. Then, the post-hoc Tukey’s test also revealed
dramatic differences between MSP & FDRP (P<0.001) and MSP & HP (P<0.001); but no sta-
tistical differences between FDRP & HP (P = 0.320) in IL-27. In TGF-β1, the data indicated
compelling differences between MSP & HP (P<0.001). On the plus side, differences were seen
between MSP & FDRP (P = 0.171) and FDRP & HP (P = 0.060) in TGF-β1, yet none was statis-
tically significant (Table 2 & Fig 2A and 2C).
Furthermore, the eight-week treatment with vitamin D3 indicated statistical differences
among study groups in terms of mRNA expression surfaces of IL-27 (P<0.001) and TGF-β1
(P<0.001) in PBMCs. Herein, the mRNA expression of IL-27 and TGF-β1 have up-regulated
in all groups but MSP holds the highest mRNA expression in relative FDRP and HP [ΔCT IL-
27: MSP: 3.63±1.50 vs. FDRP: 5.25±1.26 vs. HP: 6.29±1.25; ΔCT TGF-β1: MSP: 4.28±0.96 vs.
FDRP: 5.39±1.74 vs. HP: 6.83±1.55]. What is more, pair-wise comparisons explicated differ-
ences between each two groups in IL-27 (MSP & FDRP: P<0.001, FDRP & HP: P = 0.023,
MSP & HP: P<0.001) and TGF-β1 (MSP & FDRP: P = 0.023, FDRP & HP: P = 0.002, MSP &
HP: P<0.001 (Table 2 & Fig 2B and 2D).
Additionally, the outcomes of paired t-test analyses–in all study groups, especially in MSP-
indicated that the administration of vitamin D3 up-regulates the production of IL-27 and
TGF-β1, as anti-inflammatory cytokines. The observed fold changes in MSP were 5.4 for IL-27
(P<0.001) and 4.3 for TGF-β1 (P<0.001), and the obtained fold changes for FDRP were also
reported 4.7 for IL-27 (P<0.001) and 3.5 for TGF-β1 (P = 0.002). After all, the fold changes in
HP were 3.5 for IL-27 (P<0.001) and 2.7 for TGF-β1 (P = 0.007) (Table 2).
3.3. The plasma levels of inflammatory parameters before and after
supplementation
Before beginning the supplementation of vitamin D3, the plasma levels of IL-27 and IL-10 in
MSP were considerably lower than that FDRP and HP [(IL-27: MSP: 119.19±19.90 vs. FDRP:
Table 2. Interleukin ΔCT in before and after eight weeks of treatment with vitamin D3.
Variables MSP, n = 25 FDRP, n = 25 HP, n = 25 P�
Before After Before After Before After Before After
IL-27 (mean±SD) 5.93±1.49 3.63±1.50 7.54±1.28 5.25±1.26 8.09±1.23 6.29±1.25 <0.001 <0.001
P�� AB<0.001 AB<0.001 BC = 0.320 BC = 0.023 AC<0.001 AC<0.001
Fold changes† - 5.4 - 4.7 - 3.5
P��� - <0.001 - <0.001 - <0.001
TGF-β1(mean±SD) 6.49±1.13 4.28±0.96 7.18±1.66 5.39±1.74 8.06±1.16 6.83±1.55 <0.001 <0.001
P�� AB = 0.171 AB = 0.023 BC = 0.060 BC = 0.002 AC<0.001 AC<0.001
Fold changes† - 4.3 - 3.5 - 2.7
P��� - <0.001 - 0.002 - 0.007
The data are represented as mean ± standard deviation (SD). One-way ANOVA and then, post-hoc Tukey’s test were applied to the analysis of differences between
groups. Within-group comparisons of mRNA expression surfaces of IL-27 and TGF-β1 were also fulfilled by using the paired t-test. Between-group differences, pairwise
comparisons (Tukey’s test), and within-group differences were shown by P�, P��, and P���, respectively. Likewise, MSP, FDRP, and HP were represented by A, B, and C.
P<0.05 shows the statistical significance, and the sign † stands for the expression surfaces of cytokines in comparison with the baseline values, according to the ratio
formula (2-ΔΔCT). Abbreviations: ANOVA, analysis of variance; IL, Interleukin; TGF-β1: transforming growth factor-β; MSP, Multiple Sclerosis Participants; FDRP,
First-Degree Relative Participants; HP, Healthy Participants.
https://doi.org/10.1371/journal.pone.0231145.t002
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Fig 2. The outcome of IL-27 & TGF-β1 mRNA expression analysis. Impacts of vitamin D3 administration on mRNA expression of anti-inflammatory cytokines
(n = 25 per group). (A-D) IL-27 and TGF-β1 mRNA expression surfaces of Multiple Sclerosis Participants (MSP), First Degree Relatives Participants (FDRP), and
Healthy Participants (HP). In comparison, among groups, MSP, FDRP, and HP have been identified by A, B, and C, respectively. One-way ANOVA and then, post-hoc
Tukey’s test, was applied. The data were then represented as mean ± standard deviation (SD), and � P<0.05 was considered as statistically significant between groups.
https://doi.org/10.1371/journal.pone.0231145.g002
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128.16±14.95 and HP: 139.01±15.59; P<0.001; Table 3 & Fig 3) (IL-10: MSP: 212.10±12.74 vs.
FDRP: 219.64±27.97 and HP: 229.77±22.96; P = 0.022; Table 3 & Fig 3)] while, no statistical
difference was found in plasma concentrations of TGF-β1 among three groups (MSP: 164.92
±22.75 vs. FDRP: 173.45±18.85 and HP: 168.94±20; P = 0.347; Table 3 & Fig 3). Interestingly,
higher IL-6 and IL-17A plasma levels were found in MSP in comparison with FDRP and HP
[(IL-6: MSP: 167.37±32.82 vs. FDRP: 110.39±34.04 and HP: 130.27±18.42; P<0.001) (IL-17A:
MSP: 96.76±25.57 vs. FDRP: 67.44±18 and HP: 75.72±16.64; P<0.001) Table 3 & Fig 3]. Also,
as is represented by the post-hoc Tukey’s test in Table 3, there were significant differences
between MSP & HP (P<0.001) in IL-27, between MSP & FDRP (P<0.001) and MSP & HP
(P = 0.001) in IL-17A; MSP & HP (P = 0.017) in IL-10; MSP & FDRP (P<0.001), MSP & HP
(P<0.001), and between FDRP and HP (P = 0.049) in IL-6.
The changed plasma levels of IL-27, TGF- β1, IL-10, IL-17A, and IL-6 after the administra-
tion of vitamin D3 are illustrated in Table 3 and Fig 3. It is worth mentioning that in this
period, the plasma levels of TGF- β1 [MSP: 258.58±30.83 vs. FDRP: 183.74±19.09 and HP:
179.41±18.55; (P<0.001)], IL-17A [MSP: 76.10±21.39 vs. FDRP: 61.10±14.96 and HP: 59.71
±18.28; (P = 0.004)], and IL-6 [MSP: 136.83±32.92 vs. FDRP: 89.87±25.39 and HP: 96.21
±16.34; (P<0.001)] were significantly different among the three groups. Meanwhile, serious
differences were not observed across MSP, FDRP, and HP in IL-27 [MSP: 138.81±19.39 vs.
FDRP: 141.35±19.05 and HP: 147.35±18.13; (P = 0.266)] and IL-10 [MSP: 241.45±28.06 vs.
FDRP: 232.88±18.48 and HP: 242.39±27.51; (P = 0.341)]. Nevertheless, pair-wise comparisons
indicated differences between MSP & FDRP (P<0.001) and MSP & HP (P<0.001) in TGF- β1;
MSP & FDRP (P = 0.014) and MSP & HP (P = 0.007) in IL-17A; MSP & FDRP (P<0.001) and
MSP & HP (P<0.001) in IL-6.
Table 3. Plasma levels (pg/ml) of cytokines before and after eight weeks of treatment with vitamin D3.
Variables MSP, n = 25 FDRP, n = 25 HP, n = 25 P�
Before After Before After Before After Before After
IL-27 (mean±SD) 119.19±19.90 138.81±19.39 128.16±14.95 141.35±19.05 139.01±15.59 147.35±18.13 <0.001 0.266
P�� AB = 0.155 AB = 0.883 BC = 0.068 BC = 0.502 AC<0.001 AC = 0.252
P��� - 0.001 - 0.002 - 0.096
TGF-β1(mean±SD) 164.92±22.75 258.58±30.83 173.45±18.85 183.74±19.09 168.94±20 179.41±18.55 0.347 <0.001
P�� AB = 0.314 AB<0.001 BC = 0.720 BC = 0.793 AC = 0.770 AC<0.001
P��� - <0.001 - 0.109 - 0.069
IL-10 (mean±SD) 212.10±12.74 241.45±28.06 219.64±27.97 232.88±18.48 229.77±22.96 242.39±27.51 0.022 0.341
P�� AB = 0.455 AB = 0.453 BC = 0.245 BC = 0.378 AC = 0.017 AC = 0.990
P��� - <0.001 - 0.026 - 0.066
IL-17A (mean±SD) 96.76±25.57 76.10±21.39 67.44±18 61.10±14.96 75.72±16.64 59.71±18.28 <0.001 0.004
P�� AB<0.001 AB = 0.014 BC = 0.330 BC = 0.962 AC = 0.001 AC = 0.007
P��� - 0.024 - 0.204 - 0.001
IL-6 (mean±SD) 167.37±32.82 136.83±32.92 110.39±34.04 89.87±25.39 130.27±18.42 96.21±16.34 <0.001 <0.001
P�� AB<0.001 AB<0.001 BC = 0.049 BC = 0.662 AC<0.001 AC<0.001
P��� - <0.001 - 0.003 - <0.001
The data are represented as mean ± standard deviation (SD). One-way ANOVA and then, post-hoc Tukey’s test were applied to the analysis of differences between
groups. Within-group comparisons of mRNA expression surfaces of IL-27 and TGF-β1 were also fulfilled by using the paired t-test. Between-group differences, pairwise
comparisons (Tukey’s test), and within-group differences were shown by P�, P��, and P���, respectively. Likewise, MSP, FDRP, and HP were represented by A, B, and C.
P<0.05 shows the statistical significance, and the sign † stands for the expression surfaces of cytokines in comparison with the baseline values, according to the ratio
formula (2-ΔΔCT). Abbreviations: ANOVA, analysis of variance; IL, Interleukin; TGF-β1: transforming growth factor-β; MSP, Multiple Sclerosis Participants; FDRP,
First-Degree Relative Participants; HP, Healthy Participants.
https://doi.org/10.1371/journal.pone.0231145.t003
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On top of this, the paired T-test elucidated that IL-27 (P = 0.001), TGF- β1 (P<0.001), and
IL-10 (P<0.001) up-regulate, and in contrast, IL-17A (P = 0.024), and IL-6 (P<0.001) down-
regulate the treatment with vitamin D3 in MSP, whereas TGF- β1 (P = 0.109) and IL-17A
(P = 0.204) in FDRP as well as IL-27 (P = 0.096), TGF- β1 (P = 0.069), and IL-10 (P = 0.066) in
HP do not represent any statistical indications of any changes in the plasma levels (Table 3).
4. Discussion
The main purpose of the study in hand was to survey IL-27 and TGF-β1 mRNA expression at
the molecular level along with the protein levels of IL-27, TGF-β1, IL-17A, IL-10, and IL-6
concerning the potential impression of vitamin D3 in gene expression and immune system.
The present paper was designed based on two control groups, including FDRP and HP, along-
side MSP to investigate the prominent role of vitamin D3 in MS patients. In our previous
study [5], schematic primitives, so-called the Seesaw model, were proposed for fluctuation of
IL-10 as a major anti-inflammatory as well as IL-17A and IL-6 as a crucial pro-inflammatory
cytokines by vitamin D3 which clarified that the up-regulation of IL-10 and down-regulation
of IL-17A and IL-6 had occurred at adequate sera levels of vitamin D3. In this study, the Seesaw
model was extended through entrancing IL-27 and TGF-β1 which have been introduced as
key factors in the production of IL-10, IL-17A, and IL-6 (Fig 4), and their possible roles in mis-
adjusting pro- and anti-inflammatory state via alteration of vitamin D3 sera level were eluci-
dated as well.
This study indicated that the protein concentrations of anti-inflammatory cytokines (IL-27,
TGF- β1, and IL-10) in MSP had uplifted with an eight-week treatment with vitamin D3 while
the plasma levels of pro-inflammatory cytokines (IL-17A and IL-6) had decreased in this
group. Interestingly, the cytokines-mediated immunity exerts crucial effects on the pathophys-
iological progress of autoimmune diseases, such as MS. The aberrant expression of pro- and
anti-inflammatory cytokines may be the underlying reason for autoimmune disorders based
on the reports [23]. Since MS is an autoimmune disorder characterized by neuronal damage,
demyelination, and chronic inflammation, it seems that cytokines are significant inflammation
mediators. In particular, IL-27 and TGF- β modify inflammation and can be secreted directly
at inflammatory sites in the CNS during MS [16, 24]. In agreement with this paper’s findings,
Tang et al. [7] explored the role of IL-27 in MS patients and reported that plasma and mRNA
expression levels of IL-27 had declined in MS patients. Besides, they indicated that plasma lev-
els of IL-27 are negatively correlated to the percentages of circulating Th17 or plasma IL-17
concentrations in patients, suggesting its involvement in the pathophysiological process of
MS.
Moreover, the same results were reported by Babaloo et al. [25] in which the expression
level of IL-27 had decreased against increasing IL-17A in untreated MS patients compared to
the healthy controls. Accordingly, they have suggested a suppressive role of IL-27 on the
inflammatory process of MS. In an animal study, Mohammadi-Kordkhayli et al. [19] evaluated
the impact of vitamin D supplementation on IL-27 expression levels in the experimental auto-
immune encephalomyelitis (EAE) and proved that compared to a control group, the
Fig 3. The outcome of IL-27, TGF-β1, IL-17A, IL-10 & IL-6 protein levels analysis. Effects of vitamin D3
administration on plasma concentrations of cytokines in Multiple Sclerosis Participants (MSP), First Degree Relatives
Participants (FDRP), and Healthy Participants (HP) (n = 25 per group). One-way ANOVA and then, post-hoc Tukey’s
test, was applied. We observed that supplementation with vitamin D3 had significantly effect in changing plasma levels
of IL-27, TGF-β1, IL-17A, IL-10 & IL-6 in MSP group (A), while, only the plasma levels of IL-6, IL-10 & IL-27 in FDRP
group (B) and IL-17A & IL-6 in HP group (C) changed. Mean ± standard deviation (SD) and asterisk (�) represents the
differences before and after supplementation, also, P<0.05 was considered as statistically significant between groups.
https://doi.org/10.1371/journal.pone.0231145.g003
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expression level of IL-27 P28 and IL-27 EBI3 was powerfully up-surged in vitamin D-treated
group. Their study suggests that IL-27 via promoting IL-10 secretion and suppressing the
inflammatory effects of IL-17A plays a pivotal role in ameliorating clinical symptoms and the
development of MS disorder. It appears that cell differentiation of either T-reg or Th17
depends on TGF-β. Interestingly, naïve T cells become the T-reg cell in the presence of TGF- β
(without IL-6), while, in the presence of IL-6, they lead to Th-17 cell differentiation [26]. In
other words, the TGF- β/IL-6 ratio may be a remarkable factor in differentiating naïve CD4+
cells to Th17 or T-reg cells [27]. Ahangar-Parvin et al. [13] illustrated that the expression of
TGF-β up-regulates in EAE mice after vitamin D3 supplementation. Interestingly enough, a
similar finding has been demonstrated by Aivo et al. [18] in MS patients. On top of this, Roll-
nik et al. [28] illuminated that the expression level of TGF- β1 had declined in MS patients’
sera compared with the control group and Ishikawa et al. [29] confirmed that TGF-β1 was able
to improve clinical EAE and inhibit relapse phase in them.
Nevertheless, in several studies, contradictory results have also been reported. For instance,
Naderi et al. [30] found that the plasma level of IL-27 in MS patients had up-surged in compar-
ison with healthy controls, and Pot et al. [31] also indicated these results in cerebrospinal fluid
(CSF). Concurrently, Lalive et al. [24] had acknowledged an increase in IL-27 levels in the CSF
but not in the sera of MS patients compared with healthy subjects. Additionally, Farsani et al.
[32] investigated the effect of vitamin D3 on the expression level of the TGF-β1 gene in PBMCs
of MS patients in comparison with healthy control, but they did not observe any remarkable
alterations in gene expression before and after treatment. Moreover, in another study con-
ducted by Isik et al. [33], the association between TGF- β1 expression and vitamin D3 defi-
ciency was assessed in patients who had been referred to Endocrinology and Metabolic
Diseases Clinic which resulted in that TGF- β1 was negatively correlated with vitamin D3, par-
ticularly in patients with lower than 5 ng/ml 25(OH) vitamin D3 levels. It is interesting to note
that a variety of factors could contribute to such inconsistency outcomes as reported in various
studies including sample size and various geographical regions, cell types, genetic inheritance
in participants and the crucially double-faced or pleiotropic role of IL-27 and TGF- β1 and, in
some of studies, polymorphisms in Vitamin D Receptor (VDR) genes [6, 13, 30, 34].
Based on the accumulated data of our present and previous [34] studies, another major con-
clusion is related to the key role of IL-27 and TGF- β1 in the expression of pro- and anti-
inflammatory cytokines in human immune system, especially in terms of chronic inflamma-
tion of the central nervous system like MS (Fig 4). Following this, based on the observed differ-
ences and the literature cited, which has clarified a relationship between the cytokines, it
suggests that IL-27 and TGF- β1 are key regulators of IL-10, IL-17A, and IL-6 production.
Increasing the expression of IL-27 and TGF- β1 leads to a sufficient intake of vitamin D3, and
two crucial mechanisms occur in the immune system that creates anti-inflammatory states: 1)
both of which directly affect the expression of IL-10, thereby leaving positive feedback on up-
regulation of major anti-inflammatory cytokine (IL-10); 2) IL-27 and TGF- β1 have inhibiting
impacts on the expression level of IL-17A and result in negative feedback on up-regulation of
this pro-inflammatory interleukin. In this regard, Fitzgerald et al. [35] elucidated that the up-
Fig 4. Seesaw model. (A): When the sera level of vitamin D is sufficient, the anti-inflammatory state will come true. Thereby, at the first step, the expression
levels of IL-27 and TGF-β1 augment. Then, the effectiveness of these cytokines has been represented separately by 1. negative feedback on the IL-17A
expression, and 2. Positive feedback on the IL-10 expression as a major anti-inflammatory. After that, the pro-inflammatory state is prohibited. (B): Conversely,
pro-inflammatory cytokines, especially IL-17A, increases during the deficiency level of vitamin D3. IL-17A mediates BBB dysfunction (so, pro-inflammatory
cytokines can cross the BBB) and induces secretion of IL-6 by BBB endothelial. However, after the production of IL-6 and in the presence of TGF-β1 in
inflammation tissue, IL-6 has positive feedback on increasing IL-17A secretion, too. TGF-β1: Transforming Growth Factor-β1, BBB: Blood-Brain Barrier, IL:
Interleukin.
https://doi.org/10.1371/journal.pone.0231145.g004
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regulation of IL-10 through increasing the expression of IL-27 was related to less production
of IL-17, and exogenous IL-27 could decline the severity of adoptively transferred EAE by a
pathway which could link to IL-10. On the other hand, IL-27 could directly influence the regu-
latory T cell population to produce more IL-10 [8, 15]. Furthermore, more studies reported
that IL-27 could quell inflammation state through prohibiting the function and the differentia-
tion of Th17 cells, particularly repression to the secretion of IL-17A via JAK1-STAT1 [36], fol-
lowed by ameliorated clinical symptoms and development of MS disease [11, 19, 35]. Various
studies have illustrated the role of TGF- β1 in inciting the production of IL-10 [32, 37, 38], and
also, it has become elucidated that TGF-β1 can trigger IL-10 through Smad4 pathway [16]. Fol-
lowing the same issue, TGF- β1 could repress the differentiation of naive CD4+ T cells into
pathogenic Th17 ones and down-regulate the mRNA expression of IL-17 due to the immuno-
suppressive traits [39–41]. However, there are contradictory results about the impact of TGF-
β1 on the differentiation of Th17 to IL-17 in a way that some of them indicated that TGF- β1
was able to trigger the differentiation of Th17 to IL-17 [42, 43]. Moreover, the production of
IL-17A had increased in the pro-inflammatory state due to the deficiency level of vitamin D3
[44]. After that, IL-17A could mediate BBB dysfunction (so, pro-inflammatory cytokines could
cross the BBB) and induce the secretion of IL-6 by BBB endothelial. What is more, the pres-
ence of TGF-β1 in inflammation tissue leading to the induction of FOXP3 expression in
peripheral T cells together with IL-6 could stimulate T cell differentiation into Th-17 cells,
which–as a subsequence—could increase the surface of IL-17A production [45, 46]. Addition-
ally, the composition of IL-6 and TGF- β1 could up-regulate RORγt mRNA, acting as a key
regulator of the Th17 cell differentiation and activation of the STAT3 transcription factor [47,
48].
According to these findings, the Seesaw model—expressing the importance of the sera level
of vitamin D3 in fluctuation and balance of anti- and pro-inflammatory cytokines, as well as
this model—could highlight the significance of IL-27 and TGF- β1 in preventing inflammation
state in the immune system, particularly in MS patients. Consolidation and appropriate equi-
librium of the schematic Seesaw model by enough levels of vitamin D3 appeared to be suggest-
ing a reasonable mechanism for protection from MS by dietary modulations. Thus far, the
roles of IL-27 and TGF- β1 and their association with other cytokines in MS disorder as a het-
erogeneous and complex autoimmune have been inconsistent and contradictory. Moreover,
surveys are implicated in confirming the present model and illuminating the precise effect of
IL-27 and TGF- β1 in terms of amelioration or development of MS. More probably, epigenetic
nutritional mechanisms may be a milestone in finding a solution to such contradictions. Fur-
ther, recent studies have also suggested that interactions between environmental factors,
including vitamin D3, bioactive components, and hormones with epigenetic parameters are of
principal reasons for MS. Because of their beneficial impressions on crucial TF engaged in
neurodegeneration and axonal damage, dietary factors are also remarkably modifiable. There-
fore, further investigations with using complementary and novel techniques such as flow
cytometry, as well as taking into consideration of correlation the observed changes in cyto-
kines to clinical and psychological measures of disease (EDSS, DASS, MRI measurements,
etc.) alongside real time-PCR and ELISA are essential to improve therapeutic approaches and
deal with all contradictions regarding the molecular mechanisms preoccupied in MS [49, 50].
The most obvious finding to emerge from this study was that the up-regulation of IL-27
and TGF- β1 could occur at adequate serum levels of vitamin D3, exclusively in MS patients.
As stated, IL-27 and TGF- β1 could have positive feedback on the up-regulation of IL-10, and
conversely, they could also have negative feedback on the up-regulation of IL-17A and IL-6.
Due to this reason, IL-27 and TGF-β1 could have a major role in the immunomodulatory
function and also could contribute to the prevention of the pathophysiological process of MS.
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